Zkusit zdarma
Mesoblast Limited

Mesoblast Limited

MESO
Cena:
$ 15.20
+0.22 (1.47%)
Valuace
70
Růst
53
Zdraví
71
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

20:55 29-04-2026

Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Repo...

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain

20:53 28-04-2026

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader...

Gregory George Acquires 1,981,890 Shares of Mesoblast (NASDAQ:MESO) Stock

Gregory George Acquires 1,981,890 Shares of Mesoblast (NASDAQ:MESO) Stock

4:19 12-04-2026

Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George bought 1,981,890 shares o...

Gregory George Purchases 4,000,000 Shares of Mesoblast (NASDAQ:MESO) Stock

Gregory George Purchases 4,000,000 Shares of Mesoblast (NASDAQ:MESO) Stock

4:19 12-04-2026

Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George acquired 4,000,000 shares...

Gregory George Buys 2,324,072 Shares of Mesoblast (NASDAQ:MESO) Stock

Gregory George Buys 2,324,072 Shares of Mesoblast (NASDAQ:MESO) Stock

4:19 12-04-2026

Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George acquired 2,324,072 shares...

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION

16:09 10-04-2026

Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification a...

Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript

Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript

1:56 09-04-2026

Mesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript...

Why Mesoblast's Move Into DMD Warrants A Speculative Buy (Upgrade)

Why Mesoblast's Move Into DMD Warrants A Speculative Buy (Upgrade)

13:26 08-04-2026

Mesoblast (MESO) is upgraded to a speculative Buy as Ryoncil outperforms in pediatric SR-aGVHD and a...

Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation

Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation

9:07 08-04-2026

Mesoblast outlines commercial strategy to double net revenues as Ryoncil ® approaches US$100M net r...

Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy

Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy

23:35 07-04-2026

Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible ...

Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter

Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter

21:03 06-04-2026

Strong growth in February/March following January seasonality Net revenue approaches US$100M since l...

Mesoblast to Host R&D Day on April 8, 2026

Mesoblast to Host R&D Day on April 8, 2026

19:19 17-03-2026

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader...

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

19:21 11-03-2026

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader...

Mesoblast Financial Results and Corporate Update Webcast

Mesoblast Financial Results and Corporate Update Webcast

7:00 20-02-2026

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ...

Mesoblast (NASDAQ:MESO) Stock Price Passes Below 50-Day Moving Average – Time to Sell?

Mesoblast (NASDAQ:MESO) Stock Price Passes Below 50-Day Moving Average – Time to Sell?

2:01 17-02-2026

Mesoblast Limited (NASDAQ: MESO - Get Free Report) shares passed below its 50 day moving average dur...

Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy

Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy

8:11 12-02-2026

In a press release on Wednesday, it was noted that Ryoncil has shown high survival rates in patients...

High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD

High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD

18:27 11-02-2026

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ...

Mesoblast: Real-World Data Validates The Bull Case For Ryoncil

Mesoblast: Real-World Data Validates The Bull Case For Ryoncil

5:59 11-02-2026

Mesoblast (MESO) is demonstrating rapid revenue growth post-Ryoncil launch, with Q4 gross sales up 6...

Mesoblast (NASDAQ:MESO) Share Price Passes Below 50-Day Moving Average – Time to Sell?

Mesoblast (NASDAQ:MESO) Share Price Passes Below 50-Day Moving Average – Time to Sell?

4:38 07-02-2026

Shares of Mesoblast Limited (NASDAQ: MESO - Get Free Report) passed below its 50 day moving average ...

Ryoncil® Net Revenues Increase for the Quarter to US$30M

Ryoncil® Net Revenues Increase for the Quarter to US$30M

18:54 28-01-2026

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader ...

close

HIGH SURVIVAL RATES WITH RYONCIL® IN EIND PROGRAM EMPHASIZE IMPORTANCE OF EARLIER USE IN BOTH CHILDREN AND ADULTS WITH SR-AGVHD

11-02-2026
NEW YORK, FEB. 11, 2026 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER ...
Více zde

RYONCIL® NET REVENUES INCREASE FOR THE QUARTER TO US$30M

28-01-2026
NEW YORK, JAN. 28, 2026 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER ...
Více zde

REAL-WORLD COMMERCIAL EXPERIENCE WITH RYONCIL® SHOWS 84% SURVIVAL OF CHILDREN WITH SR-AGVHD AFTER COMPLETING 28-DAYS OF TREATMENT

26-01-2026
NEW YORK, JAN. 26, 2026 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER ...
Více zde

FDA ACKNOWLEDGES EFFECTS ON PAIN INTENSITY FAVOR REXLEMESTROCEL-L, CONFIRMS 12-MONTH REDUCTION IN BACK PAIN SUPPORTS PRODUCT EFFICACY

18-01-2026
NEW YORK, JAN. 18, 2026 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER ...
Více zde

RYONCIL® SALES INCREASE 60% IN DECEMBER QUARTER TO US$35.1M

08-01-2026
STRONG BALANCE SHEET REFLECTS REVENUE GROWTH AND NEW $125M FIVE-YEAR FACILITY STRONG BALANCE SHEET R...
Více zde

MESOBLAST ANNOUNCES CHANGES TO BOARD OF DIRECTORS' LEADERSHIP ROLES

01-01-2026
NEW YORK, JAN. 01, 2026 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER ...
Více zde

MESOBLAST RETIRES SENIOR DEBT WITH NON-DILUTIVE, LOWER COST, FIVE-YEAR CREDIT LINE

29-12-2025
MESOBLAST HAS OPTION TO DRAW DOWN UP TO US$125 MILLION BY JUNE 30, 2026 NEW FACILITY DOES NOT ENCUMB...
Více zde

INDEPENDENT STUDY PRESENTED AT AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING CONCLUDES REMESTEMCEL-L SUPERIOR TO RUXOLITINIB IN CLINICAL OUTCOMES AS TREATMENT FOR SR-AGVHD

11-12-2025
NEW YORK, DEC. 11, 2025 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER ...
Více zde

MESOBLAST PARTICIPATION AT PIPER SANDLER CONFERENCE

03-12-2025
NEW YORK, DEC. 03, 2025 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER ...
Více zde

MESOBLAST TRADING UPDATE AT ANNUAL GENERAL MEETING HIGHLIGHTS CONTINUED STRONG GROWTH IN RYONCIL® REVENUE

24-11-2025
NEW YORK, NOV. 24, 2025 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER ...
Více zde

MESOBLAST AND BMT CTN TO INITIATE PIVOTAL TRIAL OF RYONCIL® AS PART OF FIRST-LINE REGIMEN IN ADULTS WITH SEVERE ACUTE GVHD REFRACTORY TO STEROIDS

20-11-2025
NEW YORK, NOV. 20, 2025 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER ...
Více zde

JAMES M. O'BRIEN APPOINTED CHIEF FINANCIAL OFFICER AT MESOBLAST

17-11-2025
NEW YORK, NOV. 17, 2025 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER ...
Více zde

MESOBLAST TO MEET WITH FDA NEXT MONTH TO DISCUSS REXLEMESTROCEL-L AND OPIOID CESSATION

04-11-2025
NEW YORK, NOV. 04, 2025 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER ...
Více zde

RYONCIL® NET REVENUES INCREASE 69% IN SECOND QUARTER POST LAUNCH

19-10-2025
NEW YORK, OCT. 19, 2025 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER ...
Více zde

RYONCIL® REVENUES INCREASE 66% IN SECOND QUARTER POST LAUNCH

06-10-2025
NEW YORK, OCT. 06, 2025 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER ...
Více zde

RYONCIL® RECEIVES J-CODE FROM MEDICARE & MEDICAID SERVICES (CMS) FACILITATING REIMBURSEMENT AND BROADER PATIENT ACCESS

02-10-2025
NEW YORK, OCT. 02, 2025 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER ...
Více zde

MESOBLAST CELL THERAPY PRODUCTS ARE DESIGNATED U.S. ORIGIN AND NOT SUBJECT TO TARIFFS

26-09-2025
NEW YORK, SEPT. 26, 2025 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER...
Více zde

SUCCESSFUL COMMERCIAL LAUNCH OF RYONCIL® HIGHLIGHTED AT GLOBAL HEALTHCARE CONFERENCES

14-09-2025
NEW YORK, SEPT. 14, 2025 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER...
Více zde

MESOBLAST ENTERS INTO OPTION TO ISSUE US$50 MILLION CONVERTIBLE NOTES

03-09-2025
NEW YORK, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER...
Více zde

BANNER YEAR FOR MESOBLAST WITH FIRST FDA PRODUCT APPROVAL AND SUCCESSFUL COMMERCIAL LAUNCH OF RYONCIL®

28-08-2025
FINANCIAL RESULTS AND OPERATIONAL UPDATE FOR THE FULL YEAR ENDED JUNE 30, 2025 FINANCIAL RESULTS AND...
Více zde

SUCCESSFUL COMMERCIAL LAUNCH OF RYONCIL®

17-07-2025
NEW YORK, JULY 17, 2025 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER ...
Více zde

MESOBLAST AND FDA ALIGN ON KEY ITEMS FOR REVASCOR® BIOLOGIC LICENSE APPLICATION IN ISCHEMIC HEART FAILURE

30-06-2025
NEW YORK, JUNE 30, 2025 (GLOBE NEWSWIRE) -- MESOBLAST (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER IN ALLOG...
Více zde

MESOBLAST MAINTAINS MOMENTUM WITH FDA ON ACCELERATED APPROVAL PATHWAY FOR REVASCOR® IN ISCHEMIC HEART FAILURE AND LABEL EXTENSION FOR RYONCIL® IN ADULTS WITH GVHD

11-06-2025
NEW YORK, JUNE 11, 2025 (GLOBE NEWSWIRE) -- MESOBLAST (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER IN ALLOG...
Více zde

FDA PROVIDES SEVEN YEARS OF ORPHAN-DRUG EXCLUSIVE APPROVAL FOR RYONCIL®

14-05-2025
NEW YORK, MAY 14, 2025 (GLOBE NEWSWIRE) -- MESOBLAST (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER IN ALLOGE...
Více zde

APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED MARCH 31, 2025

29-04-2025
NEW YORK, APRIL 29, 2025 (GLOBE NEWSWIRE) -- MESOBLAST LIMITED (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER...
Více zde

MESOBLAST APPOINTS CORPORATE FINANCE LEADER LYN COBLEY TO BOARD

28-04-2025
NEW YORK, APRIL 28, 2025 (GLOBE NEWSWIRE) -- MESOBLAST (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER IN ALLO...
Více zde

MESOBLAST EXTENDS PAYER COVERAGE FOR RYONCIL® TO OVER 100 MILLION US LIVES

16-04-2025
NEW YORK, APRIL 16, 2025 (GLOBE NEWSWIRE) -- MESOBLAST (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER IN ALLO...
Více zde

MESOBLAST ALLOGENEIC CELL THERAPY PRODUCTS ARE DESIGNATED ‘U.S. COUNTRY OF ORIGIN' AND NOT SUBJECT TO U.S. TARIFFS

03-04-2025
NEW YORK, APRIL 03, 2025 (GLOBE NEWSWIRE) -- MESOBLAST (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER IN ALLO...
Více zde

MESOBLAST FILES REQUEST FOR TYPE B MEETING WITH FDA TO DISCUSS ACCELERATED APPROVAL PATHWAY FOR REVASCOR® IN ISCHEMIC HEART FAILURE

02-04-2025
NEW YORK, APRIL 02, 2025 (GLOBE NEWSWIRE) -- MESOBLAST (NASDAQ:MESO; ASX:MSB), GLOBAL LEADER IN ALLO...
Více zde

FIRST THREE CHILDREN TO COMMENCE TREATMENT WITH RYONCIL®

30-03-2025
UNITED STATES CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) MANDATES RYONCIL® COVERAGE UNITED ST...
Více zde

close

Dokumenty nejsou k dispozici

preloader